#BEGIN_DRUGCARD DB03323

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
69-79-4

# ChEBI_ID:
17306

# Chemical_Formula:
C12H22O11

# Chemical_IUPAC_Name:
(2S,3R,4R,5S,6S)-2-(hydroxymethyl)-6-{[(2S,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}oxane-3,4,5-triol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A dextrodisaccharide from malt and starch. It is used as a sweetening agent and fermentable intermediate in brewing. (Grant & Hackh&#39;s Chemical Dictionary, 5th ed)

# Dosage_Forms:
Not Available

# Drug_Category:
Sweetening Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
7.8E+005 mg/L (at 20 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Maltose

# HET_ID:
MAL

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5-,6+,7+,8+,9-,10+,11+,12-/m0/s1

# InChI_Key:
InChIKey=GUBGYTABKSRVRQ-AEDSEYDFSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C00208

# KEGG_Drug_ID:
D00044

# LIMS_Drug_ID:
3323

# Mechanism_Of_Action:
Not Available

# Melting_Point:
102-103 °C

# Molecular_Weight_Avg:
342.2965

# Molecular_Weight_Mono:
342.116211546

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1R6Z

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-3

# Predicted_LogS:
0.23

# Predicted_Water_Solubility:
5.86e+02 g/l

# Primary_Accession_No:
DB03323

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936190

# PubChem_Substance_ID:
46508819

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02111

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC[C@@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@H]2CO)[C@@H](O)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:08 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X78145

# Drug_Target_1_GenBank_ID_Protein:
510492

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
cgt

# Drug_Target_1_Gene_Sequence:
>2142 bp
ATGAAGAAATTTCTGAAATCGACAGCTGCGCTTGCCCTGGGATTATCGCTGACGTTCGGG
CTTTTCAGCCCTGCCCAGGCCGCGCCGGATACCTCGGTATCCAACAAGCAAAATTTCAGC
ACCGACGTCATCTATCAAATTTTCACCGACAGGTTTTCGGACGGCAATCCCGCCAACAAT
CCGACCGGCGCGGCGTTTGACGGAACCTGCACGAACCTCCGGCTGTATTGCGGCGGCGAC
TGGCAGGGCATCATCAACAAAATCAACGACGGTTACCTGACCGGGATGGGCGTTACCGCC
ATCTGGATCTCCCAGCCGGTCGAAAACATCTACAGCATCATCAATTATTCCGGCGTAAAC
AACACGGCCTATCACGGCTACTGGGCCCGGGACTTCAAGAAGACGAATCCGGCCTACGGC
ACGATTGCGGACTTCCAGAACCTGATCGCCGCCGCGCATGCAAAAAACATCAAAGTCATT
ATCGACTTTGCCCCGAACCATACGTCGCCCGCCTCGTCCGACCAGCCTTCCTTTGCGGAA
AACGGCCGGCTGTACGATAACGGCACGCTGCTCGGGGGATACACGAACGATACGCAGAAC
CTGTTCCACCATAACGGCGGCACGGACTTTTCCACGACCGAAAACGGCATCTACAAAAAC
CTGTACGATCTCGCCGACCTGAACCATAACAACAGCACCGTGGACGTCTACTTGAAGGAC
GCGATCAAAATGTGGCTGGACCTCGGCATCGACGGCATCCGCATGGATGCGGTGAAGCAT
ATGCCGTTCGGCTGGCAGAAGAGCTTTATGGCTGCCGTCAACAACTATAAGCCGGTCTTT
ACCTTCGGCGAATGGTTCCTGGGCGTAAATGAAGTGAGCCCGGAAAACCATAAGTTTGCC
AACGAATCCGGCATGAGCCTGCTTGATTTCCGTTTTGCCCAAAAGGTGCGGCAGGTGTTC
CGGGACAACACCGACAATATGTACGGCCTGAAGGCGATGCTGGAGGGCTCCGCAGCCGAT
TACGCCCAGGTGGATGACCAGGTGACGTTCATCGACAACCATGACATGGAGCGTTTCCAC
GCAAGCAATGCAAACCGCCGGAAGCTGGAGCAAGCGCTTGCGTTCACGCTGACCTCGCGC
GGCGTCCCCGCCATTTATTACGGCACCGAGCAGTACATGTCGGGCGGGACCGATCCGGAC
AACCGGGCGCGGATCCCTTCCTTCTCCACGTCGACGACCGCCTATCAGGTCATTCAAAAG
CTGGCGCCGCTGCGCAAGTGCAACCCGGCCATCGCCTACGGATCGACGCAGGAGCGCTGG
ATCAACAACGACGTGCTCATTTATGAGCGCAAATTCGGCAGCAACGTTGCCGTCGTTGCC
GTCAACCGCAATTTAAACGCGCCGGCTTCCATTTCGGGACTTGTCACTTCCCTGCCGCAA
GGCAGCTACAACGACGTCCTTGGCGGCCTTCTGAACGGCAACACGTTATCGGTAGGCTCC
GGCGGGGCCGCCTCCAATTTCACGCTTGCGGCCGGCGGCACGGCGGTGTGGCAGTACACC
GCGGCTACGGCGACGCCGACCATCGGGCATGTCGGGCCGATGATGGCCAAGCCGGGCGTG
ACGATCACGATCGACGGCCGCGGCTTCGGCTCTAGCAAAGGCACCGTCTACTTCGGTACG
ACGGCGGTGAGCGGGGCGGACATCACGTCTTGGGAAGACACGCAGATCAAAGTGAAAATT
CCGGCCGTCGCAGGCGGCAACTACAACATTAAAGTCGCAAACGCTGCCGGAACGGCAAGC
AATGTGTATGACAACTTCGAGGTATTGTCCGGAGACCAGGTCAGCGTCCGCTTCGTGGTC
AACAACGCGACGACGGCCCTTGGGCAAAATGTGTACCTGACGGGCAGTGTCAGCGAGCTG
GGGAACTGGGACCCGGCAAAAGCAATCGGGCCGATGTACAATCAGGTCGTTTACCAATAT
CCGAACTGGTATTATGACGTCAGCGTTCCGGCCGGCAAAACGATCGAGTTCAAGTTTTTG
AAAAAACAAGGCTCCACCGTCACGTGGGAAGGCGGCAGCAACCACACCTTCACCGCGCCG
TCCAGCGGCACCGCGACCATTAACGTGAATTGGCAGCCATAA

# Drug_Target_1_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_1_General_References:
7493956	Knegtel RM, Strokopytov B, Penninga D, Faber OG, Rozeboom HJ, Kalk KH, Dijkhuizen L, Dijkstra BW: Crystallographic studies of the interaction of cyclodextrin glycosyltransferase from Bacillus circulans strain 251 with natural substrates and products. J Biol Chem. 1995 Dec 8;270(49):29256-64.
8107143	Lawson CL, van Montfort R, Strokopytov B, Rozeboom HJ, Kalk KH, de Vries GE, Penninga D, Dijkhuizen L, Dijkstra BW: Nucleotide sequence and X-ray structure of cyclodextrin glycosyltransferase from Bacillus circulans strain 251 in a maltose-dependent crystal form. J Mol Biol. 1994 Feb 18;236(2):590-600.
8672460	Strokopytov B, Knegtel RM, Penninga D, Rozeboom HJ, Kalk KH, Dijkhuizen L, Dijkstra BW: Structure of cyclodextrin glycosyltransferase complexed with a maltononaose inhibitor at 2.6 angstrom resolution. Implications for product specificity. Biochemistry. 1996 Apr 2;35(13):4241-9.
8955113	Penninga D, van der Veen BA, Knegtel RM, van Hijum SA, Rozeboom HJ, Kalk KH, Dijkstra BW, Dijkhuizen L: The raw starch binding domain of cyclodextrin glycosyltransferase from Bacillus circulans strain 251. J Biol Chem. 1996 Dec 20;271(51):32777-84.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2523

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
77310

# Drug_Target_1_Name:
Cyclomaltodextrin glucanotransferase

# Drug_Target_1_Number_of_Residues:
713

# Drug_Target_1_PDB_ID:
2CXG

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00128	Alpha-amylase
PF00686	CBM_20
PF01833	TIG
PF02806	Alpha-amylase_C

# Drug_Target_1_Protein_Sequence:
>Cyclomaltodextrin glucanotransferase precursor
MKKFLKSTAALALGLSLTFGLFSPAQAAPDTSVSNKQNFSTDVIYQIFTDRFSDGNPANN
PTGAAFDGTCTNLRLYCGGDWQGIINKINDGYLTGMGVTAIWISQPVENIYSIINYSGVN
NTAYHGYWARDFKKTNPAYGTIADFQNLIAAAHAKNIKVIIDFAPNHTSPASSDQPSFAE
NGRLYDNGTLLGGYTNDTQNLFHHNGGTDFSTTENGIYKNLYDLADLNHNNSTVDVYLKD
AIKMWLDLGIDGIRMDAVKHMPFGWQKSFMAAVNNYKPVFTFGEWFLGVNEVSPENHKFA
NESGMSLLDFRFAQKVRQVFRDNTDNMYGLKAMLEGSAADYAQVDDQVTFIDNHDMERFH
ASNANRRKLEQALAFTLTSRGVPAIYYGTEQYMSGGTDPDNRARIPSFSTSTTAYQVIQK
LAPLRKCNPAIAYGSTQERWINNDVLIYERKFGSNVAVVAVNRNLNAPASISGLVTSLPQ
GSYNDVLGGLLNGNTLSVGSGGAASNFTLAAGGTAVWQYTAATATPTIGHVGPMMAKPGV
TITIDGRGFGSSKGTVYFGTTAVSGADITSWEDTQIKVKIPAVAGGNYNIKVANAAGTAS
NVYDNFEVLSGDQVSVRFVVNNATTALGQNVYLTGSVSELGNWDPAKAIGPMYNQVVYQY
PNWYYDVSVPAGKTIEFKFLKKQGSTVTWEGGSNHTFTAPSSGTATINVNWQP

# Drug_Target_1_Reaction:
Cyclizes part of a 1,4-alpha-D-glucan chain by formation of a 1,4-alpha-D-glucosidic bond

# Drug_Target_1_Signals:
1-27

# Drug_Target_1_Specific_Function:
Cyclizes part of a 1,4-alpha-D-glucan chain by formation of a 1,4-alpha-D-glucosidic bond

# Drug_Target_1_SwissProt_ID:
P43379

# Drug_Target_1_SwissProt_Name:
CDGT2_BACCI

# Drug_Target_1_Synonyms:
CGTase
Cyclodextrin-glycosyltransferase
Cyclomaltodextrin glucanotransferase precursor
EC 2.4.1.19

# Drug_Target_1_Theoretical_pI:
6.52

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
AMY2B

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6967

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
Not Available

# Drug_Target_2_Name:
Alpha-amylase 2B

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
Not Available

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P19961

# Drug_Target_2_SwissProt_Name:
AMY2B_HUMAN

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
Not Available

# Drug_Target_3_Cellular_Location:
Cytoplasmic

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
Not Available

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
AJ001089

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
aglA

# Drug_Target_3_Gene_Sequence:
>1380 bp
ATGCCATCTGTGAAGATCGGTATCATCGGTGCGGGGAGCGCGGTGTTTTCTCTGAGGCTT
GTGAGTGATCTTTGCAAAACGCCGGGACTCTCTGGCAGCACGGTCACCCTCATGGATATC
GACGAAGAAAGACTCGACGCTATTCTGACCATCGCGAAAAAATACGTTGAAGAAGTGGGA
GCGGATCTGAAATTCGAAAAAACCATGAATTTAGATGACGTCATCATCGACGCGGATTTT
GTGATAAACACAGCGATGGTGGGTGGCCATACCTACTTGGAGAAGGTCAGACAGATCGGT
GAGAAATACGGCTACTACAGAGGAATAGACGCTCAGGAGTTTAACATGGTCTCCGACTAC
TACACCTTCTCCAACTACAACCAGCTCAAGTACTTCGTTGACATAGCAAGGAAGATAGAG
AAGCTCTCCCCAAAAGCCTGGTACTTGCAGGCAGCGAACCCCATTTTCGAGGGAACAACC
CTTGTGACAAGAACGGTTCCCATAAAGGCAGTGGGATTCTGCCATGGACACTACGGCGTG
ATGGAGATCGTAGAGAAACTGGGGCTGGAAGAAGAAAAAGTAGATTGGCAGGTCGCAGGA
GTGAACCACGGTATCTGGCTGAATAGGTTCAGATACAACGGGGGGAACGCGTATCCCCTC
CTTGACAAGTGGATCGAGGAAAAATCAAAAGATTGGAAACCAGAGAACCCCTTCAACGAC
CAGCTCTCTCCCGCCGCGATAGACATGTACAGATTCTACGGTGTGATGCCCATCGGTGAC
ACCGTGAGAAACTCTTCGTGGAGGTACCACAGGGATCTTGAAACCAAGAAGAAGTGGTAC
GGTGAACCCTGGGGAGGAGCAGATTCTGAAATAGGCTGGAAATGGTACCAAGACACGCTT
GGAAAGGTCACGGAGATCACAAAGAAGGTGGCAAAGTTCATCAAAGAAAATCCGTCCGTG
AGGCTCTCCGACCTTGGAAGTGTTCTGGGGAAAGACCTCTCAGAAAAGCAGTTTGTGCTC
GAAGTGGAGAAAATTCTCGATCCAGAAAGAAAGAGTGGAGAGCAGCACATCCCATTCATC
GATGCGCTGCTGAACGATAACAAGGCAAGATTCGTGGTGAACATACCAAATAAAGGTATC
ATTCACGGAATAGACGATGACGTGGTTGTTGAAGTCCCAGCCCTTGTGGACAAGAACGGA
ATCCATCCCGAGAAGATCGAACCACCGCTTCCAGATCGCGTGGTCAAGTACTACCTGAGA
CCCAGAATCATGAGGATGGAAATGGCTCTGGAGGCGTTTCTAACGGGTGACATAAGGATC
ATAAAAGAACTTCTCTACAGAGATCCAAGGACAAAGAGCGATGAACAGGTAGAAAGGTGA

# Drug_Target_3_General_Function:
Involved in hydrolase activity, hydrolyzing O-glycosyl compounds

# Drug_Target_3_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.
10972187	Raasch C, Streit W, Schanzer J, Bibel M, Gosslar U, Liebl W: Thermotoga maritima AglA, an extremely thermostable NAD+-, Mn2+-, and thiol-dependent alpha-glucosidase. Extremophiles. 2000 Aug;4(4):189-200.
12062450	Raasch C, Armbrecht M, Streit W, Hocker B, Strater N, Liebl W: Identification of residues important for NAD+ binding by the Thermotoga maritima alpha-glucosidase AglA, a member of glycoside hydrolase family 4. FEBS Lett. 2002 Apr 24;517(1-3):267-71.
12588867	Lodge JA, Maier T, Liebl W, Hoffmann V, Strater N: Crystal structure of Thermotoga maritima alpha-glucosidase AglA defines a new clan of NAD+-dependent glycosidases. J Biol Chem. 2003 May 23;278(21):19151-8. Epub 2003 Feb 14.
9453151	Bibel M, Brettl C, Gosslar U, Kriegshauser G, Liebl W: Isolation and analysis of genes for amylolytic enzymes of the hyperthermophilic bacterium Thermotoga maritima. FEMS Microbiol Lett. 1998 Jan 1;158(1):9-15.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
4343

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
55048

# Drug_Target_3_Name:
Alpha-glucosidase

# Drug_Target_3_Number_of_Residues:
480

# Drug_Target_3_PDB_ID:
1OBB

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF02056	Glyco_hydro_4

# Drug_Target_3_Protein_Sequence:
>Alpha-glucosidase
MPSVKIGIIGAGSAVFSLRLVSDLCKTPGLSGSTVTLMDIDEERLDAILTIAKKYVEEVG
ADLKFEKTMNLDDVIIDADFVINTAMVGGHTYLEKVRQIGEKYGYYRGIDAQEFNMVSDY
YTFSNYNQLKYFVDIARKIEKLSPKAWYLQAANPIFEGTTLVTRTVPIKAVGFCHGHYGV
MEIVEKLGLEEEKVDWQVAGVNHGIWLNRFRYNGGNAYPLLDKWIEEKSKDWKPENPFND
QLSPAAIDMYRFYGVMPIGDTVRNSSWRYHRDLETKKKWYGEPWGGADSEIGWKWYQDTL
GKVTEITKKVAKFIKENPSVRLSDLGSVLGKDLSEKQFVLEVEKILDPERKSGEQHIPFI
DALLNDNKARFVVNIPNKGIIHGIDDDVVVEVPALVDKNGIHPEKIEPPLPDRVVKYYLR
PRIMRMEMALEAFLTGDIRIIKELLYRDPRTKSDEQVEKVIEEILALPENEEMRKHYLKR

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Alpha-glycosidase with a very broad specificity. Hydrolyzes maltose and other small maltooligosaccharides but is inactive against the polymeric substrate starch. AglA is not specific with respect to the configuration at the C-4 position of its substrates because glycosidic derivatives of D-galactose are also hydrolyzed. Does not cleave beta-glycosidic bonds

# Drug_Target_3_SwissProt_ID:
O33830

# Drug_Target_3_SwissProt_Name:
AGLA_THEMA

# Drug_Target_3_Synonyms:
EC 3.2.1.20
Maltase

# Drug_Target_3_Theoretical_pI:
5.75

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
Not Available

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
AJ252161

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
malE

# Drug_Target_4_Gene_Sequence:
>1284 bp
GTGTCGGTGAGGAGATGGGGAATCGTATCGACAGGTGTGGCCGCGCTCGTGTTGGCGGGC
GGAGCCATCGCGGGCTGTGGAACCTCGAACGGTGGTCAAAACACGTCTCCTTCCACGAGC
TCGTCGAGCGCCAAAGGGGAGGCAAGCGCTCTGCCCAAAGGGCAGACCATCACCGTTTGG
TCGTGGCAGACAGGGCCGGAGTTGCAAGACGTGAAGCAGATCGCCGCTCAGTGGGCAAAG
GCTCATGGGGACAAGGTCATTGTCGTCGACCAAAGCTCCAATCCGAAGGGATTCCAGTTC
TACGCCACGGCGGCTCGCACGGGCAAGGGGCCTGATGTCGTGTTTGGAATGCCGCACGAC
AACAATGGCGTTTTCGCAGAAGAAGGATTGATGGCGCCGGTACCGTCTGGCGTGCTCAAC
ACGGGTCTCTATGCACCTAATACGATCGACGCCATCAAGGTCAACGGCACGATGTACTCG
GTGCCAGTATCCGTTCAGGTCGCGGCAATCTACTACAACAAAAAGCTTGTGCCGCAGCCA
CCGCAGACATGGGCCGAATTCGTGAAAGACGCAAATGCACATGGCTTCATGTATGACCAA
GCGAATCTTTACTTCGATTACGCCATTATCGGCGGCTATGGCGGGTATGTGTTCAAGGAC
AACAACGGCACACTCGACCCGAACAACATAGGTCTTGACACACCGGGGGCTGTGCAGGCT
TACACGCTGATGAGGGATATGGTCTCCAAGTATCACTGGATGACCCCGAGCACGAATGGC
TCTATCGCGAAGGCTGAGTTTCTGGCTGGGAAGATTGGTATGTACGTGAGTGGCCCATGG
GACACGGCGGATATTGAGAAGGCCAAAATTGACTTCGGTGTAACGCCATGGCCCACCTTG
CCGAACGGCAAGCATGCCACGCCCTTCTTAGGCGTTATCACGGCATTTGTGAACAAGGAG
TCCAAGACCCAGGCAGCTGACTGGAGCCTTGTTCAAGCGTTGACCAGTGCGCAGGCGCAG
CAAATGTACTTCAGAGATTCCCAGCAGATTCCTGCGCTCTTGTCTGTGCAGAGGTCGAGC
GCCGTCCAGTCGAGCCCAACCTTTAAAGCGTTCGTCGAACAGTTGCGCTACGCGGTACCG
ATGCCCAACATTCCGCAAATGCAGGCCGTGTGGCAAGCAATGAGCATCCTGCAGAATATC
ATTGCGGGCAAGGTGTCACCAGAGCAGGGTGCGAAGGATTTTGTGCAAAACATTCAAAAA
GGCATCATGGCACAAGGATCCTGA

# Drug_Target_4_General_Function:
Involved in maltose transmembrane transporter activity

# Drug_Target_4_General_References:
11053372	Hulsmann A, Lurz R, Scheffel F, Schneider E: Maltose and maltodextrin transport in the thermoacidophilic gram-positive bacterium Alicyclobacillus acidocaldarius is mediated by a high-affinity transport system that includes a maltose binding protein tolerant to low pH. J Bacteriol. 2000 Nov;182(22):6292-301.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
5209

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
45674

# Drug_Target_4_Name:
Maltose binding protein

# Drug_Target_4_Number_of_Residues:
427

# Drug_Target_4_PDB_ID:
1URS

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF01547	SBP_bac_1

# Drug_Target_4_Protein_Sequence:
>Maltose binding protein
MSVRRWGIVSTGVAALVLAGGAIAGCGTSNGGQNTSPSTSSSSAKGEASALPKGQTITVW
SWQTGPELQDVKQIAAQWAKAHGDKVIVVDQSSNPKGFQFYATAARTGKGPDVVFGMPHD
NNGVFAEEGLMAPVPSGVLNTGLYAPNTIDAIKVNGTMYSVPVSVQVAAIYYNKKLVPQP
PQTWAEFVKDANAHGFMYDQANLYFDYAIIGGYGGYVFKDNNGTLDPNNIGLDTPGAVQA
YTLMRDMVSKYHWMTPSTNGSIAKAEFLAGKIGMYVSGPWDTADIEKAKIDFGVTPWPTL
PNGKHATPFLGVITAFVNKESKTQAADWSLVQALTSAQAQQMYFRDSQQIPALLSVQRSS
AVQSSPTFKAFVEQLRYAVPMPNIPQMQAVWQAMSILQNIIAGKVSPEQGAKDFVQNIQK
GIMAQGS

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
1-26

# Drug_Target_4_Specific_Function:
Not Available

# Drug_Target_4_SwissProt_ID:
Q9RHZ6

# Drug_Target_4_SwissProt_Name:
Q9RHZ6_ALIAC

# Drug_Target_4_Synonyms:
Maltose binding protein precursor

# Drug_Target_4_Theoretical_pI:
8.73

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Cytoplasmic

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
Not Available

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
AE000513

# Drug_Target_5_GenBank_ID_Protein:
Not Available

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
treZ

# Drug_Target_5_Gene_Sequence:
>1803 bp
TCACCCCACCAACACCGCTTCCCCCGCCCCCAGCGTCAAATCCTCGCGCCCTTCGGTATG
CAGCAGCAGGCGCCTAGGCACGGTGAAGGGCAACTTGACCTCGGCGACGGCCCGCGTGTC
CTGGCCCAGGTTCCACAGCAGCACCCGCTCGCCTGCGCCGGTCACGGTACGGACCCACAG
CACGTCGCCGTCGTGGCCGGTGGTCAGGTTCTCGCGCTGGCGGTTGTGCAGCACCGGGTC
CTCGCGCCGCAGCCGCAGCAGGTCGCGGTACAGGCGCAGGGTGCGGGCGTGTTCGCCGCC
CTCGCGCTCGGCCCAGTTCAGTTTGGAGTTGAGGAAAGTCTGCTCGGCCTGCGGGTCGGG
CACGTCCTCGCCGCTGAAGCCGCTGAAGCCCCCGAATTCCTTTTTGCGGCCTTCGGATAC
GGCCTGTCCCAACTCGCCCGCGTGGTCGCTGAAAAACTGAAACGGCGTGCTGGCAGCCCA
TTCCTGGCCCTGAAACAGCAGCGGGGTCATCGGCAGCAGCAGCGCGGCGGCGCCCCGGTA
CTCGTGCAGCGTCACTCCGTCCGACTGGTGCAGCCGCTCGCCCAGGGGCCGGTTGCCGAT
CTGGTCGTGGTTCTGGATGCAGTAGACGAAGTTGGGGGCCTCCAGCGCGTCGGAGGGGTG
GCCGCGCTCGTGCTCCTCGCCCTTGACCGCCCAGAACTGCCCCTCGTAGCGCCAGCCCCG
GCGGATGGTGTAGGCGAGGGCTTCGGCGCCGCCCCGGTAGCCGGCGTAGTAGCCTTCCTG
CTCGCCGGTCAGGGTGACGCGCGTTTCGTGGTGAAAGTCGTCGGTCCAGATGCCGTCGAG
GTGGTTGACCGTCACCAGGTCGGGCAGGTTGCGGTGATCCTCGGCGAGCAGCAGGTGGGT
GCCGCCGAGTTCGTGAATTTCCTGCGCCAGCTCGGTCAGGATGTGGGTCTCGCTGTCGTC
GGTCATGTACGGCGTGGCGTCGAGCCGCAGCCCGTCGAAGTGGTAATCGCGCAGCCACAT
GCGGGCGTTGCCGGTGACGTAGCGGCGCATGTGCGGCTCGGCGTAGTCCAACCCCATGCC
CCAGGCGCTCGAAAAGCGGTCGGTAAAATAGCTCGGCGCGTAGCTGCTCAGGTAATTGCC
TGACGGCCCGAAGTGGTTGTACACCACGTCCAGAAATACGCCCAGCCCCAGTCGGTGCGC
GGCATCTACCAGGGCCATCAGGTCCTCAGGGCGGCCATACGGCGCGTAGGGCGCGTAAAA
GGCGGCGCCGTCGTAGCCCCAGCCGCGCTGCCCGTCAAAGGCGGCGAGCGGCATCACTTG
AATGGCCGTCACGCCCAGCTCTTTCAGGTACGGCAGCTTCTCGGCGGCGGCGCGGTAGGT
GCCTTCCGGGGTAAAGGTGCCCACATGCACCTCGTAGAACACGCAGTCGGCGAGTTTGAT
GCCGTGCCAGTCGGCGTCTGTCCAGTCGAAGGTGCCGAAGTCCACCACTTCCGCTTCGCC
GTGCACGCCGTCGGGCAAAAAGCGGGCGTAGGGGTCGGGGGTTGGCACGCCGTCGAGCAC
GAAAAGGTAGCGGGCGCCGGGGCCGACCGGCAGTTCCAGTTCGTAGATGCCGCCGCCGAG
CGAGGTCATGACGTGCTCGGTGCCGTTCACGCGCACGGCCACCGTGCGGGCGGTGGAGGT
CCACAGGCGAAAGCGGGTGCCCGCGCCGCCGGGCAGGGGCGTGGCGCCCAGACGGGTGCG
CGGGTCGTGCTGGGTCTGAAAAGAAGCGGGGGGGGTCGGGGTCACAGGCTGGGTCTGGGT
CAT

# Drug_Target_5_General_Function:
Involved in catalytic activity

# Drug_Target_5_General_References:
10567266	White O, Eisen JA, Heidelberg JF, Hickey EK, Peterson JD, Dodson RJ, Haft DH, Gwinn ML, Nelson WC, Richardson DL, Moffat KS, Qin H, Jiang L, Pamphile W, Crosby M, Shen M, Vamathevan JJ, Lam P, McDonald L, Utterback T, Zalewski C, Makarova KS, Aravind L, Daly MJ, Minton KW, Fleischmann RD, Ketchum KA, Nelson KE, Salzberg S, Smith HO, Venter JC, Fraser CM: Genome sequence of the radioresistant bacterium Deinococcus radiodurans R1. Science. 1999 Nov 19;286(5444):1571-7.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
5056

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
66910

# Drug_Target_5_Name:
Maltooligosyltrehalose trehalohydrolase, putative

# Drug_Target_5_Number_of_Residues:
600

# Drug_Target_5_PDB_ID:
2BHU

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00128	Alpha-amylase
PF02922	Isoamylase_N

# Drug_Target_5_Protein_Sequence:
>Maltooligosyltrehalose trehalohydrolase, putative
MTQTQPVTPTPPASFQTQHDPRTRLGATPLPGGAGTRFRLWTSTARTVAVRVNGTEHVMT
SLGGGIYELELPVGPGARYLFVLDGVPTPDPYARFLPDGVHGEAEVVDFGTFDWTDADWH
GIKLADCVFYEVHVGTFTPEGTYRAAAEKLPYLKELGVTAIQVMPLAAFDGQRGWGYDGA
AFYAPYAPYGRPEDLMALVDAAHRLGLGVFLDVVYNHFGPSGNYLSSYAPSYFTDRFSSA
WGMGLDYAEPHMRRYVTGNARMWLRDYHFDGLRLDATPYMTDDSETHILTELAQEIHELG
GTHLLLAEDHRNLPDLVTVNHLDGIWTDDFHHETRVTLTGEQEGYYAGYRGGAEALAYTI
RRGWRYEGQFWAVKGEEHERGHPSDALEAPNFVYCIQNHDQIGNRPLGERLHQSDGVTLH
EYRGAAALLLPMTPLLFQGQEWAASTPFQFFSDHAGELGQAVSEGRKKEFGGFSGFSGED
VPDPQAEQTFLNSKLNWAEREGGEHARTLRLYRDLLRLRREDPVLHNRQRENLTTGHDGD
VLWVRTVTGAGERVLLWNLGQDTRAVAEVKLPFTVPRRLLLHTEGREDLTLGAGEAVLVG

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Not Available

# Drug_Target_5_SwissProt_ID:
Q9RX51

# Drug_Target_5_SwissProt_Name:
TREZ_DEIRA

# Drug_Target_5_Synonyms:
Not Available

# Drug_Target_5_Theoretical_pI:
5.26

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Periplasm

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
V00303

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
malE

# Drug_Target_6_Gene_Sequence:
Not Available

# Drug_Target_6_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_6_General_References:
1420181	Sharff AJ, Rodseth LE, Spurlino JC, Quiocho FA: Crystallographic evidence of a large ligand-induced hinge-twist motion between the two domains of the maltodextrin binding protein involved in active transport and chemotaxis. Biochemistry. 1992 Nov 10;31(44):10657-63.
2002054	Spurlino JC, Lu GY, Quiocho FA: The 2.3-A resolution structure of the maltose- or maltodextrin-binding protein, a primary receptor of bacterial active transport and chemotaxis. J Biol Chem. 1991 Mar 15;266(8):5202-19.
6088507	Duplay P, Bedouelle H, Fowler A, Zabin I, Saurin W, Hofnung M: Sequences of the malE gene and of its product, the maltose-binding protein of Escherichia coli K12. J Biol Chem. 1984 Aug 25;259(16):10606-13.
6088520	Froshauer S, Beckwith J: The nucleotide sequence of the gene for malF protein, an inner membrane component of the maltose transport system of Escherichia coli. Repeated DNA sequences are found in the malE-malF intercistronic region. J Biol Chem. 1984 Sep 10;259(17):10896-903.
6185687	Bedouelle H, Schmeissner U, Hofnung M, Rosenberg M: Promoters of the malEFG and malK-lamB operons in Escherichia coli K12. J Mol Biol. 1982 Nov 15;161(4):519-31.
6283312	Bedouelle H, Hofnung M: A DNA sequence containing the control regions of the malEFG and malK-lamB operons in Escherichia coli K12. Mol Gen Genet. 1982;185(1):82-7.
8265357	Blattner FR, Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL: Analysis of the Escherichia coli genome. IV. DNA sequence of the region from 89.2 to 92.8 minutes. Nucleic Acids Res. 1993 Nov 25;21(23):5408-17.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.
9309217	Quiocho FA, Spurlino JC, Rodseth LE: Extensive features of tight oligosaccharide binding revealed in high-resolution structures of the maltodextrin transport/chemosensory receptor. Structure. 1997 Aug 15;5(8):997-1015.
9600841	Wilkins MR, Gasteiger E, Tonella L, Ou K, Tyler M, Sanchez JC, Gooley AA, Walsh BJ, Bairoch A, Appel RD, Williams KL, Hochstrasser DF: Protein identification with N and C-terminal sequence tags in proteome projects. J Mol Biol. 1998 May 8;278(3):599-608.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
3668

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
43388

# Drug_Target_6_Name:
Maltose-binding periplasmic protein precursor

# Drug_Target_6_Number_of_Residues:
396

# Drug_Target_6_PDB_ID:
1LLS

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF01547	SBP_bac_1

# Drug_Target_6_Protein_Sequence:
>Maltose-binding periplasmic protein precursor
MKIKTGARILALSALTTMMFSASALAKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIK
VTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTW
DAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEP
YFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAE
AAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKE
LAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIP
QMSAFWYAVRTAVINAASGRQTVDEALKDAQTRITK

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
1-26

# Drug_Target_6_Specific_Function:
Involved in the high-affinity maltose membrane transport system malEFGK. Initial receptor for the active transport of and chemotaxis toward maltooligosaccharides

# Drug_Target_6_SwissProt_ID:
P0AEX9

# Drug_Target_6_SwissProt_Name:
MALE_ECOLI

# Drug_Target_6_Synonyms:
MMBP
Maltodextrin-binding protein

# Drug_Target_6_Theoretical_pI:
5.37

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Cytoplasmic

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
AB024519

# Drug_Target_7_GenBank_ID_Protein:
4520330

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
spoII

# Drug_Target_7_Gene_Sequence:
>1641 bp
ATGAAAAATCAGTTTCAATATTGTTGTATTGTCATTTTGTCTGTAGTGATGTTATTTGTA
TCATTATTAATTCCGCAAGCGAGTTCGGCAGCTGTAAATGGAAAAGGAATGAATCCAGAT
TACAAAGCATATTTAATGGCGCCATTAAAAAAGATACCGGAAGTAACAAATTGGGAGACA
TTTGAAAATGATTTACGATGGGCAAAACAAAATGGTTTTTATGCTATTACAGTTGATTTT
TGGTGGGGGGATATGGAAAAGAACGGAGATCAGCAATTTGATTTTTCATACGCACAGCGC
TTTGCTCAATCGGTAAAAAATGCAGGTATGAAAATGATTCCTATTATTTCCACACATCAG
TGCGGTGGAAATGTTGGGGATGATTGCAATGTACCAATTCCTTCATGGGTTTGGAATCAA
AAATCCGATGATAGCCTTTATTTTAAGTCTGAAACAGGAACTGTCAATAAAGAAACATTA
AATCCACTTGCTTCAGATGTAATTCGAAAGGAATATGGTGAACTATATACAGCATTCGCA
GCAGCTATGAAACCGTATAAAGATGTAATTGCAAAAATATATTTATCTGGAGGACCAGCT
GGTGAACTAAGATATCCTTCATATACAACTTCCGATGGGACAGGATATCCCTCACGTGGA
AAGTTTCAAGCGTATACAGAGTTTGCAAAATCTAAATTTCGTTTATGGGTATTAAATAAA
TATGGTTCTCTAAATGAAGTGAATAAAGCATGGGGCACGAAACTGATTTCAGAGTTAGCA
ATTTTACCACCAAGCGATGGGGAACAATTCTTAATGAATGGATATCTTTCTATGTATGGA
AAAGACTATTTAGAATGGTATCAGGGCATCTTGGAAAATCATACAAAATTAATTGGTGAA
TTAGCACATAACGCATTTGACACAACTTTCCAAGTACCAATTGGTGCAAAAATTGCAGGC
GTACATTGGCAATATAATAACCCAACAATACCTCATGGAGCTGAAAAGCCTGCAGGGTAT
AATGATTATAGCCATTTACTTGATGCTTTCAAAAGTGCAAAGCTAGATGTAACATTTACT
TGCTTAGAAATGACAGATAAAGGTAGTTATCCGGAATATTCAATGCCAAAAACATTGGTA
CAAAATATTGCAACATTAGCCAATGAAAAGGGAATTGTATTAAACGGTGAAAATGCTTTA
AGTATCGGAAATGAAGAAGAGTATAAAAGAGTTGCAGAAATGGCTTTCAATTATAATTTT
GCTGGATTTACGTTACTTCGTTATCAAGATGTAATGTATAACAATTCATTAATGGGGAAA
TTTAAAGATTTATTAGGTGTAACCCCTGTTATGCAAACGATTGTAGTAAAAAATGTTCCT
ACAACAATAGGAGATACTGTTTATATTACTGGGAATCGTGCGGAATTAGGAAGTTGGGAC
ACAAAACAGTATCCAATTCAATTATATTATGATTCTCATAGTAATGATTGGAGAGGAAAT
GTTGTGTTGCCAGCTGAAAGAAATATAGAATTTAAAGCATTTATTAAAAGTAAAGATGGA
ACGGTTAAATCATGGCAAACAATACAACAAAGTTGGAATCCAGTGCCACTAAAGACTACC
TCTCATACAAGTAGTTGGTAA

# Drug_Target_7_General_Function:
Involved in beta-amylase activity

# Drug_Target_7_General_References:
10353816	Mikami B, Adachi M, Kage T, Sarikaya E, Nanmori T, Shinke R, Utsumi S: Structure of raw starch-digesting Bacillus cereus beta-amylase complexed with maltose. Biochemistry. 1999 Jun 1;38(22):7050-61.
8434930	Nanmori T, Nagai M, Shimizu Y, Shinke R, Mikami B: Cloning of the beta-amylase gene from Bacillus cereus and characteristics of the primary structure of the enzyme. Appl Environ Microbiol. 1993 Feb;59(2):623-7.

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
3365

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
61629

# Drug_Target_7_Name:
Beta-amylase

# Drug_Target_7_Number_of_Residues:
546

# Drug_Target_7_PDB_ID:
1J12

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00686	CBM_20
PF01373	Glyco_hydro_14

# Drug_Target_7_Protein_Sequence:
>Beta-amylase precursor
MKNQFQYCCIVILSVVMLFVSLLIPQASSAAVNGKGMNPDYKAYLMAPLKKIPEVTNWET
FENDLRWAKQNGFYAITVDFWWGDMEKNGDQQFDFSYAQRFAQSVKNAGMKMIPIISTHQ
CGGNVGDDCNVPIPSWVWNQKSDDSLYFKSETGTVNKETLNPLASDVIRKEYGELYTAFA
AAMKPYKDVIAKIYLSGGPAGELRYPSYTTSDGTGYPSRGKFQAYTEFAKSKFRLWVLNK
YGSLNEVNKAWGTKLISELAILPPSDGEQFLMNGYLSMYGKDYLEWYQGILENHTKLIGE
LAHNAFDTTFQVPIGAKIAGVHWQYNNPTIPHGAEKPAGYNDYSHLLDAFKSAKLDVTFT
CLEMTDKGSYPEYSMPKTLVQNIATLANEKGIVLNGENALSIGNEEEYKRVAEMAFNYNF
AGFTLLRYQDVMYNNSLMGKFKDLLGVTPVMQTIVVKNVPTTIGDTVYITGNRAELGSWD
TKQYPIQLYYDSHSNDWRGNVVLPAERNIEFKAFIKSKDGTVKSWQTIQQSWNPVPLKTT
SHTSSW

# Drug_Target_7_Reaction:
Hydrolysis of 1,4-alpha-D-glucosidic linkages in polysaccharides so as to remove successive maltose units from the non-reducing ends of the chains ALL_REAC (other) R02112 R06159(G)

# Drug_Target_7_Signals:
1-30

# Drug_Target_7_Specific_Function:
Hydrolysis of 1,4-alpha-D-glucosidic linkages in polysaccharides so as to remove successive maltose units from the non-reducing ends of the chains

# Drug_Target_7_SwissProt_ID:
P36924

# Drug_Target_7_SwissProt_Name:
AMYB_BACCE

# Drug_Target_7_Synonyms:
1,4-alpha-D-glucan maltohydrolase
Beta-amylase precursor
EC 3.2.1.2

# Drug_Target_7_Theoretical_pI:
6.72

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Cytoplasmic

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
M36539

# Drug_Target_8_GenBank_ID_Protein:
142501

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
amyM

# Drug_Target_8_Gene_Sequence:
>2154 bp
ATGAAAAAGAAAACGCTTTCTTTATTTGTGGGACTGATGCTCCTCATCGGTCTTCTGTTC
AGCGGTTCTCTTCCGTACAATCCAAACGCCGCTGAAGCCAGCAGTTCCGCAAGCGTCAAA
GGGGACGTGATTTACCAGATTATCATTGACCGGTTTTACGATGGGGACACGACGAACAAC
AATCCTGCCAAAAGTTATGGACTTTACGATCCTACCAAATCGAAGTGGAAAATGTATTGG
GGCGGGGATCTGGAGGGGGTTCGTCAAAAACTTCCTTATCTTAAACAGCTGGGCGTAACG
ACAATCTGGTTGTCCCCGGTTTTGAACAATCTGGATACACTGGCGGGCACCGATAACACG
GGCTATCACGGATACTGGACGCGCGATTTTAAACAGATTGAGGAACATTTCGGGAATTGG
ACCACATTTGACACGTTGGTCAATGATGCTCACCAAAACGGAATCAAGGTGATTGTCGAC
TTTGTGCCCAATCATTCGACTCCTTTTAAGGCAAACGATTCCACCTTTGCGGAAGGCGGC
GCCCTCTACAACAATGGAACCTATATGGGCAATTATTTTGATGACGCAACAAAAGGGTAC
TTCCACCATAATGGGGACATCAGCAACTGGGACGACCGGTACGAGGCGCAATGGAAAAAC
TTCACGGATCCAGCCGGTTTCTCGCTTGCCGATTTGTCGCAGGAAAATGGCACGATTGCT
CAATACCTGACCGATGCGGCGGTTCAATTGGTAGCACATGGTTTGCGGATTGATGCGGTG
AAGCATTTTAATTCGGGGTTCTCCAAATCGTTGGCCGATAAACTGTACCAAAAGAAAGAC
ATTTTCCTGGTGGGGGAATGGTACGGAGATGACCCCGGAACAGCCAATCATCTGGAAAAG
GTCCGGTACGCCAACAACAGCGGTGTCAATGTGCTGGATTTTGATCTCAACACGGTGATT
CGAAATGTGTTCGGCACATTTACGCAAACGATGTACGATCTTAACAATATGGTGAACCAA
ACGGGGAACGAGTACAAATACAAAGAAAATCTAATCACATTTATCGATAACCATGATATG
TCAAGATTTCTTTCGGTAAATTCGAAGAACAAGGCGAATTTGCACCAGCGCTTGCTTTCA
TTCTCACTTCGCGGGGTACGCCCTCCCATCTATTATGGAACCGAACAATACATGGCAGGC
GGCAATGACCCGTACAACCGGGGGATGATGCCGGCGTTTGATACGACAACCACCGCCTTT
AAAGAGGTGTCAACTCTGGCGGGGTTGCGCAGGAACAATGCGGCGATCCAGTACGGCACC
ACCACCCAGCGCTGGATCAACAATGATGTTTACATTTATGAACGGAAATTTTTCAACGAT
GTCGTGTTGGTGGCCATCAATCGAAACACGCAATCCTCCTATTCGATTTCCGGTTTGCAG
ACGGCCTTGCCAAATGGCAGCTATGCGGATTATCTGTCAGGGCTGTTGGGGGGGAACGGG
ATTTCCGTTTCCAATGGAAGTGTCGCTTCGTTCACGCTTGCGCCTGGAGCCGTGTCTGTT
TGGCAGTACAGCACATCCGCTTCAGCGCCGCAAATCGGATCGGTTGCTCCAAATATGGGG
ATTCCGGGTAATGTGGTCACGATCGACGGGAAAGGTTTTGGGACGACGCAGGGAACCGTG
ACATTTGGCGGAGTGACAGCGACTGTGAAATCCTGGACATCCAATCGGATTGAAGTGTAC
GTTCCCAACATGGCCGCCGGGCTGACCGATGTGAAAGTCACCGCGGGTGGAGTTTCCAGC
AATCTGTATTCTTACAATATTTTGAGTGGAACGCAGACATCGGTTGTGTTTACTGTGAAA
AGTGCGCCTCCGACCAACCTAGGGGATAAGATTTACCTGACGGGCAACATACCGGAATTG
GGGAATTGGAGCACGGATACGAGCGGAGCCGTTAACAATGCGCAAGGGCCCCTGCTCGCG
CCCAATTATCCGGATTGGTTTTATGTATTCAGCGTTCCAGCAGGAAAGACGATTCAATTC
AAGTTCTTCATCAAGCGTGCGGATGGAACGATTCAATGGGAGAATGGTTCGAACCACGTG
GCCACAACTCCCACGGGTGCAACCGGTAACATTACTGTTACGTGGCAAAACTAG

# Drug_Target_8_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_8_General_References:
10387084	Dauter Z, Dauter M, Brzozowski AM, Christensen S, Borchert TV, Beier L, Wilson KS, Davies GJ: X-ray structure of Novamyl, the five-domain "maltogenic" alpha-amylase from Bacillus stearothermophilus: maltose and acarbose complexes at 1.7A resolution. Biochemistry. 1999 Jun 29;38(26):8385-92.

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
2978

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
78676

# Drug_Target_8_Name:
Maltogenic alpha-amylase

# Drug_Target_8_Number_of_Residues:
719

# Drug_Target_8_PDB_ID:
1QHP

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00128	Alpha-amylase
PF00686	CBM_20
PF01833	TIG
PF02806	Alpha-amylase_C

# Drug_Target_8_Protein_Sequence:
>Maltogenic alpha-amylase precursor
MKKKTLSLFVGLMLLIGLLFSGSLPYNPNAAEASSSASVKGDVIYQIIIDRFYDGDTTNN
NPAKSYGLYDPTKSKWKMYWGGDLEGVRQKLPYLKQLGVTTIWLSPVLDNLDTLAGTDNT
GYHGYWTRDFKQIEEHFGNWTTFDTLVNDAHQNGIKVIVDFVPNHSTPFKANDSTFAEGG
ALYNNGTYMGNYFDDATKGYFHHNGDISNWDDRYEAQWKNFTDPAGFSLADLSQENGTIA
QYLTDAAVQLVAHGADGLRIDAVKHFNSGFSKSLADKLYQKKDIFLVGEWYGDDPGTANH
LEKVRYANNSGVNVLDFDLNTVIRNVFGTFTQTMYDLNNMVNQTGNEYKYKENLITFIDN
HDMSRFLSVNSNKANLHQALAFILTSRGTPSIYYGTEQYMAGGNDPYNRGMMPAFDTTTT
AFKEVSTLAGLRRNNAAIQYGTTTQRWINNDVYIYERKFFNDVVLVAINRNTQSSYSISG
LQTALPNGSYADYLSGLLGGNGISVSNGSVASFTLAPGAVSVWQYSTSASAPQIGSVAPN
MGIPGNVVTIDGKGFGTTQGTVTFGGVTATVKSWTSNRIEVYVPNMAAGLTDVKVTAGGV
SSNLYSYNILSGTQTSVVFTVKSAPPTNLGDKIYLTGNIPELGNWSTDTSGAVNNAQGPL
LAPNYPDWFYVFSVPAGKTIQFKFFIKRADGTIQWENGSNHVATTPTGATGNITVTWQN

# Drug_Target_8_Reaction:
hydrolysis of (1->4)-alpha-D-glucosidic linkages in polysaccharides so as to remove successive alpha-maltose residues from the non-reducing ends of the chains

# Drug_Target_8_Signals:
1-33

# Drug_Target_8_Specific_Function:
Converts starch into maltose

# Drug_Target_8_SwissProt_ID:
P19531

# Drug_Target_8_SwissProt_Name:
AMYM_GEOSE

# Drug_Target_8_Synonyms:
EC 3.2.1.133
Glucan 1,4-alpha- maltohydrolase
Maltogenic alpha-amylase precursor

# Drug_Target_8_Theoretical_pI:
5.95

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Not Available

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
X06791

# Drug_Target_9_GenBank_ID_Protein:
41964

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
malP

# Drug_Target_9_Gene_Sequence:
>2394 bp
ATGTCACAACCTATTTTTAACGATAAGCAATTTCAGGAAGCGCTTTCACGTCAGTGGCAG
CGTTATGGCTTAAATTCTGCGGCTGAAATGACTCCTCGCCAGTGGTGGCTAGCAGTGAGT
GAAGCACTGGCCGAAATGCTGCGTGCTCAGCCATTCGCCAAGCCGGTGGCGAATCAGCGA
CATGTTAACTACATCTCAATGGAGTTTTTGATTGGTCGCCTGACGGGCAACAACCTGTTG
AATCTCGGCTGGTATCAGGATGTACAGGATTCGTTGAAGGCTTATGACATCAATCTGACG
GACCTGCTGGAAGAAGAGATCGACCCGGCGCTGGGTAACGGTGGTCTGGGACGTCTGGCG
GCGTGCTTCCTCGACTCAATGGCAACTGTCGGTCAGTCTGCGACGGGTTACGGTCTGAAC
TATCAATATGGTTTGTTCCGCCAGTCTTTTGTCGATGGCAAACAGGTTGAAGCGCCGGAT
GACTGGCATCGCAGTAACTACCCGTGGTTCCGCCACAACGAAGCACTGGATGTGCAGGTA
GGGATTGGCGGTAAAGTGACGAAAGACGGACGCTGGGAGCCGGAGTTTACCATTACCGGT
CAAGCGTGGGATCTCCCCGTTGTCGGCTATCGTAATGGCGTGGCGCAGCCGCTGCGTCTG
TGGCAGGCGACGCACGCGCATCCGTTTGATCTGACTAAATTTAACGACGGTGATTTCTTG
CGTGCCGAACAGCAGGGCATCAATGCGGAAAAACTGACCAAAGTTCTCTATCCAAACGAC
AACCATACTGCCGGTAAAAAGCTGCGCCTGATGCAGCAATACTTCCAGTGTGCCTGTTCG
GTAGCGGATATTTTGCGTCGCCATCATCTGGCGGGGCGTGAACTGCACGAACTGGCGGAT
TACGAAGTTATTCAGCTGAACGATACCCACCCAACTATCGCGATTCCAGAACTGCTGCGC
GTGCTGATCGACGAGCACCAGATGAGCTGGGATGACGCTTGGGCCATTACCAGCAAAACT
TTCGCTTACACCAACCATACCCTGATGCCAGAAGCGCTGGAACGCTGGGATGTGAAACTG
GTGAAAGGCTTACTGCCGCGCCACATGCAGATTATTAACGAAATTAATACTCGCTTTAAA
ACGCTGGTAGAGAAAACCTGGCCGGGCGATGAAAAAGTGTGGGCCAAACTGGCGGTGGTG
CACGACAAACAAGTGCATATGGCGAACCTGTGTGTGGTTGGCGGTTTCGCGGTGAACGGT
GTTGCGGCGCTGCACTCGGATCTGGTGGTGAAAGATCTGTTCCCGGAATATCACCAGCTA
TGGCCGAACAAATTCCATAACGTCACCAACGGTATTACCCCACGTCGCTGGATCAAACAG
TGCAACCCGGCACTGGCGGCTCTGTTGGATAAATCACTGCAAAAAGAGTGGGCTAACGAT
CTCGATCAGCTGATCAATCTGGTTAAATTGGCTGATGATGCGAAATTCCGTGACCTTTAT
CGCGTGATCAAGCAGGCGAATAAAGTCCGTCTGGCGGAGTTTGTGAAAGTTCGTACCGGT
ATTGACATCAATCCACAGGCGATTTTCGATATTCAGATCAAACGTTTGCACGAGTACAAA
CGCCAGCACCTGAATCTGCTGCATATTCTGGCGTTGTACAAAGAAATTCGTGAAAACCCG
CAGGCTGATCGCGTACCGCGCGTCTTCCTCTTCGGCGCGAAAGCGGCACCGGGCTACTAC
CTGGCTAAGAATATTATCTTTGCGATCAACAAAGTGGCTGACGTGATCAACAACGATCCG
CTGGTTGGCGATAAGTTGAAGGTGGTGTTCCTGCCGGATTATTGCGTTTCGGCGGCGGAA
AAACTGATCCCGGCGGCGGATATCTCCGAACAAATTTCGACTGCAGGTAAAGAAGCTTCC
GGTACCGGCAATATGAAACTGGCGCTCAATGGTGCGCTTACTGTCGGTACGCTGGATGGG
GCGAACGTTGAAATCGCCGAGAAAGTCGGTGAAGAAAATATCTTTATTTTTGGTCATACG
GTGAAACAAGTGAAGGCAATTCTGGCCAAAGGCTACGACCCGGTGAAATGGCGGAAGAAA
GATAAGGTGCTGGACGCAGTATTGAAAGAGCTGGAAAGCGGTAAATACAGCGACGGCGAT
AAGCATGCCTTCGACCAGATGCTGCACAGTATCGGCAAACAGGGCGGCGATCCGTATCTG
GTGATGGCGGATTTCGCAGCCTATGTAGAGGCACAAAAGCAGGTGGATGTGCTGTACCGC
GACCAGGAGGCCTGGACTCGCGCGGCGATCCTCAATACCGCCCGCTGCGGTATGTTTAGC
TCGGATCGCTCTATTCGCGATTATCAGGCTCGTATCTGGCAGGCAAAACGCTAA

# Drug_Target_9_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_9_General_References:
10220320	O'Reilly M, Watson KA, Johnson LN: The crystal structure of the Escherichia coli maltodextrin phosphorylase-acarbose complex. Biochemistry. 1999 Apr 27;38(17):5337-45.
10469642	Watson KA, McCleverty C, Geremia S, Cottaz S, Driguez H, Johnson LN: Phosphorylase recognition and phosphorolysis of its oligosaccharide substrate: answers to a long outstanding question. EMBO J. 1999 Sep 1;18(17):4619-32.
2845225	Pugsley AP, Dubreuil C: Molecular characterization of malQ, the structural gene for the Escherichia coli enzyme amylomaltase. Mol Microbiol. 1988 Jul;2(4):473-9.
3037809	Palm D, Goerl R, Weidinger G, Zeier R, Fischer B, Schinzel R: E. coli maltodextrin phosphorylase: primary structure and deletion mapping of the C-terminal site. Z Naturforsch [C]. 1987 Apr;42(4):394-400.
3155826	Palm D, Goerl R, Burger KJ: Evolution of catalytic and regulatory sites in phosphorylases. Nature. 1985 Feb 7-13;313(6002):500-2.
6283313	Debarbouille M, Cossart P, Raibaud O: A DNA sequence containing the control sites for gene malT and for the malPQ operon. Mol Gen Genet. 1982;185(1):88-92.
6339728	Raibaud O, Debarbouille M, Schwartz M: Use of deletions created in vitro to map transcriptional regulatory signals in the malA region of Escherichia coli. J Mol Biol. 1983 Jan 25;163(3):395-408.
6986282	Schiltz E, Palm D, Klein HW: N-terminal sequences of Escherichia coli and potato phosphorylase. FEBS Lett. 1980 Jan 1;109(1):59-62.
9009262	Watson KA, Schinzel R, Palm D, Johnson LN: The crystal structure of Escherichia coli maltodextrin phosphorylase provides an explanation for the activity without control in this basic archetype of a phosphorylase. EMBO J. 1997 Jan 2;16(1):1-14.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
3091

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
90523

# Drug_Target_9_Name:
Maltodextrin phosphorylase

# Drug_Target_9_Number_of_Residues:
797

# Drug_Target_9_PDB_ID:
1QM5

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00343	Phosphorylase

# Drug_Target_9_Protein_Sequence:
>Maltodextrin phosphorylase
MSQPIFNDKQFQEALSRQWQRYGLNSAAEMTPRQWWLAVSEALAEMLRAQPFAKPVANQR
HVNYISMEFLIGRLTGNNLLNLGWYQDVQDSLKAYDINLTDLLEEEIDPALGNGGLGRLA
ACFLDSMATVGQSATGYGLNYQYGLFRQSFVDGKQVEAPDDWHRSNYPWFRHNEALDVQV
GIGGKVTKDGRWEPEFTITGQAWDLPVVGYRNGVAQPLRLWQATHAHPFDLTKFNDGDFL
RAEQQGINAEKLTKVLYPNDNHTAGKKLRLMQQYFQCACSVADILRRHHLAGRKLHELAD
YEVIQLNDTHPTIAIPELLRVLIDEHQMSWDDAWAITSKTFAYTNHTLMPEALERWDVKL
VKGLLPRHMQIINEINTRFKTLVEKTWPGDEKVWAKLAVVHDKQVHMANLCVVGGFAVNG
VAALHSDLVVKDLFPEYHQLWPNKFHNVTNGITPRRWIKQCNPALAALLDKSLQKEWAND
LDQLINLEKFADDAKFRQQYREIKQANKVRLAEFVKVRTGIEINPQAIFDIQIKRLHEYK
RQHLNLLHILALYKEIRENPQADRVPRVFLFGAKAAPGYYLAKNIIFAINKVADVINNDP
LVGDKLKVVFLPDYCVSAAEKLIPAADISEQISTAGKEASGTGNMKLALNGALTVGTLDG
ANVEIAEKVGEENIFIFGHTVEQVKAILAKGYDPVKWRKKDKVLDAVLKELESGKYSDGD
KHAFDQMLHSIGKQGGDPYLVMADFAAYVEAQKQVDVLYRDQEAWTRAAILNTARCGMFS
SDRSIRDYQARIWQAKR

# Drug_Target_9_Reaction:
(1,4-alpha-D-glucosyl)n + phosphate = (1,4-alpha-D-glucosyl)n-1 + alpha-D-glucose 1-phosphate

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Phosphorylase is an important allosteric enzyme in carbohydrate metabolism. Enzymes from different sources differ in their regulatory mechanisms and in their natural substrates. However, all known phosphorylases share catalytic and structural properties

# Drug_Target_9_SwissProt_ID:
P00490

# Drug_Target_9_SwissProt_Name:
PHSM_ECOLI

# Drug_Target_9_Synonyms:
EC 2.4.1.1

# Drug_Target_9_Theoretical_pI:
7.41

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB03323
